Evofem Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.
This NAPWHA report is an analysis drawing together several years’ worth of data from the main pharmaceutical industry suppliers of compassionate access antiretroviral (ARV) therapy in Australia and combines this with, for the first time, data from the State and Territory jurisdictions to produce the most accurate estimate to-date of the number of Medicare ineligible PLHIV in Australia. It comes with recommendations for systemic improvements.
Over the past thirteen years, many Australian women have used the drug mifepristone (RU486) to bring about a medical abortion.
Rather than undergoing a surgical abortion in a clinic or hospital operating theatre, a medical abortion is induced by taking drugs prescribed by a doctor.
But while mifepristone has been available in Australia since 2006, only some women, in some parts of the country, are able to access it. Professor Caroline de Costa argues in the Medical Journal of Australia that this needs to change.
A steady stream of Australian women with pelvic mesh implants have spent tens of thousands of dollars flying to a clinic in Missouri to have their implants removed, claiming they have suffered major side-effects from the implants used to treat prolapse and incontinence.
More than 35 Australian women have made the journey to the same practitioner because, they say, they don’t have faith in Australian surgeons to carry out a full removal of their implant.
The claim that Australia does not have the expertise is rejected by both the Australian Medical Association (AMA) and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).
Read more of Pelvic mesh implant patients want answers from Senate report
Consumers and health professionals are advised that Australasian Medical and Science Ltd (AMSL), in consultation with the TGA, has issued a hazard alert for Essure. AMSL is also recallingunused stock and withdrawing the device from the Australian market.
A new class of antibiotic has been found to work in the lab against the sexually transmitted infection gonorrhoea, which can cause infertility and damage to babies and is fast becoming resistant to all existing drugs.
Although it is early days, because the antibiotic has yet to be tried in animals or humans, researchers say they are excited by its potential.